Clinical Trials Logo

Breakthrough Cancer Pain clinical trials

View clinical trials related to Breakthrough Cancer Pain.

Filter by:

NCT ID: NCT01693328 Recruiting - Clinical trials for Breakthrough Cancer Pain

Patient Satisfaction and Quality of Life Impact - PecFent®

Qualipec
Start date: September 2012
Phase: N/A
Study type: Observational

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions. • Study objectives include assessment of early treatment satisfaction.

NCT ID: NCT01439919 Terminated - Pain Clinical Trials

A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain

ACT11705
Start date: January 2012
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of SSR411298 200 mg daily compared to placebo as adjunctive treatment for persistent cancer pain based on Numeric Rating Scale (NRS). Secondary Objectives are: - To evaluate the effect of SSR411298 200 mg daily on pain, breakthrough pain frequency, background therapy utilization, mood, patient satisfaction of pain relief, nausea, constipation, healthcare utilization and quality of life; - To evaluate the tolerability and safety of SSR411298 as adjunctive treatment for persistent cancer pain; - To characterize patient disease, in terms of cancer, cancer treatment, cancer pain and cancer pain treatment; - To evaluate the pharmacokinetic (PK) exposure of SSR411298 as adjunctive treatment for persistent cancer pain; - To assess endocannabinoid plasma concentrations.

NCT ID: NCT01045603 Completed - Clinical trials for Breakthrough Cancer Pain

Instanyl® Non-Interventional Study

INIS
Start date: December 2009
Phase: N/A
Study type: Observational

The aim of this study is to describe the use of Instanyl® (Intranasal fentanyl spray) in the treatment of breakthrough pain (BTP) in cancer patients by success of dose titration and distribution of dose strength. Data will be collected at three different time points over a 3 month period.

NCT ID: NCT00822614 Recruiting - Clinical trials for Breakthrough Cancer Pain

Safety of Fentanyl TAIFUN Treatment

FINDS
Start date: December 2008
Phase: Phase 3
Study type: Interventional

A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate hte Safety of Fentanyl TAIFUN Treatment after titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy